TOKYO, October 25, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the company has ranked first in the pharmaceuticals sector for the “2023 Award for Excellence in Corporate Disclosure” granted by the Securities Analysts Association of Japan (SAAJ) to promote the quality and fairness of corporate disclosure.
For details on regarding the “2023 Award for Excellence in Corporate Disclosure,” please refer to the website of the SAAJ.
Astellas was highly evaluated mainly in the following areas:
- Top Management committing to IR activities, and the IR group taking appropriate and prompt actions, engaging in frequent dialogue with investors
- Providing detailed materials at financial results presentations and ample explanations at briefings (including Q&As), regarding measures taken to achieve its Corporate Strategic Plan 2021 and on progress
- Its endeavors towards more effective information dissemination, for instance by actively researching stock market needs in advance
- Its positive efforts to disclose information to enhance corporate value over the medium to long term by integrating financial and non-financial information
- Holding informative events for products or R&D pipeline for which investors have high expectations
Astellas’ raison d'être is “to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.” Under this raison d'être, Astellas is delivering innovative healthcare solutions which address patients’ needs. In addition, Astellas aims to sustainably enhance its enterprise value by being chosen and trusted by all stakeholders.
In order to achieve this, Astellas discloses the value of our products on the market and results of clinical trials in a timely and appropriate manner, as well as proactively explains to stakeholders not only the features of projects under research and development, but also the potential impact on society after they are launched. In addition, we strive to create opportunities to provide information flexibly in line with the needs of stakeholders so that we do not unilaterally disseminate information. We believe these efforts for disclosure and dialogue were recognized and led to this award.
Astellas will continue to proactively engage in dialogue with stakeholders, aiming for proper market valuation, and strive to enhance and improve the quality of its disclosure.
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at https://www.astellas.com/en.
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Click below for a copy of the full press release
